SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 4, 2009, Pages 723-732

  Conroy, Andrew ^a   Stockett, David E ^a   Walker, Duncan ^b   Arkin, Michelle R ^c   Hoch, Ute ^d   Fox, Judith A ^a   Hawtin, Rachael Elizabeth ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

^b ARRAY BIOPHARMA INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEKTAR THERAPEUTICS   (United States)

Author keywords

Chronic lymphocytic leukemia; Cyclin dependent kinase; Multiple myeloma; SNS 032; Survival factors; Transcription

Indexed keywords

ANTINEOPLASTIC AGENT; AT 7519; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; FLAVOPIRIDOL; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; ROSCOVITINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EXPOSURE; DRUG POTENCY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; SOLID TUMOR; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTIPLE MYELOMA; OXAZOLES; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES;

EID: 68149162135     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0921-5     Document Type: Article

References (43)

1. AM Senderowicz EA Sausville 2000 Preclinical and clinical development of cyclin-dependent kinase modulators J Natl Cancer Inst 92 376 387
2. GI Shapiro 2006 Cyclin-dependent kinase pathways as targets for cancer treatment J Clin Oncol 24 1770 1783
3. GK Schwartz MA Shah 2005 Targeting the cell cycle: a new approach to cancer therapy J Clin Oncol 23 9408 9421
4. SV Sharma MA Fischbach DA Haber J Settleman 2006 "Oncogenic shock": explaining oncogene addiction through differential signal attenuation Clin Cancer Res 12 4392 4395
5. RG Wickremasinghe AV Hoffbrand 1999 Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies Blood 93 3587 3600
6. C Belinda SK Baliga 2002 Role of Bcl-2 family of proteins in malignancy Hematol Oncol 20 63 74
7. S Wuilleme-Toumi N Robillard P Gomez 2005 Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival Leukemia 19 1248 1252
8. DE MacCallum J Melville S Frame 2005 Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of rna polymerase II-dependent transcription and down-regulation of Mcl-1 Cancer Res 65 5399 5407
9. S Derenne B Monia NM Dean 2002 Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells Blood 100 194 199
10. P Nurse 2002 Nobel Lecture. Cyclin dependent kinases and cell cycle control Biosci Rep 22 487 499 (Pubitemid 36250188)
11. DO Morgan 1997 Cyclin-dependent kinases: engines, clocks, and microprocessors Ann Rev Cell Develop Biol 13 261 291
12. N Mailand J Diffley 2005 CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis Cell 122 915 926
13. JW Harper SJ Elledge 1998 The role of Cdk7 in CAK function, a retro-retrospective Genes Dev 12 285 289
14. P Kaldis AA Russo HS Chou NP Pavletich MJ Solomon 1998 Human and yeast Cdk-activating kinases (CAKs) display distinct substrate specificities Mol Biol Cell 9 2545 2560
15. D Fesquet N Morin M Doree A Devault 1997 Is Cdk7/cyclin H/MAT1 the genuine cdk activating kinase in cycling Xenopus egg extracts? Oncogene 15 1303 1307
16. S Akoulitchev T Makela R Weinberg D Reinberg 1995 Requirement for TFIIH kinase activity in transcription by RNA polymerase II Nature 377 557 560
17. D Busso A Keriel B Sandrock 2000 Distinct regions of MAT1 regulate cdk7 kinase and TFIIH transcription activities J Biol Chem 275 22815 22823
18. Y Hirose Y Ohkuma 2007 Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression J Biochem Tokyo 141 601 608
19. TI Lee RA Young 2000 Transcription of eukaryotic protein-coding genes Annu Rev Genet 34 77 137
20. RN Misra Xiao H-y KS Kim 2004 N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2- oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent J Med Chem 47 1719 1728
21. K Podar KC Anderson 2005 The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood 105 1383 1395
22. H Yasui T Hideshima P Richardson K Anderson 2006 Recent advances in the treatment of multiple myeloma Curr Pharm Biotechnol 7 381 393 (Pubitemid 44529196)
23. MA Frassanito A Cusmai G Iodice F Dammacco 2001 Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis Blood 97 483 489
24. S-H Chao K Fujinaga JE Marion 2000 Flavopiridol inhibits P-TEFb and blocks HIV-1 replication J Biol Chem 275 28345 28348
25. S Bach M Knockaert J Reinhardt 2005 Roscovitine targets, protein kinases and pyridoxal kinase J Biol Chem 280 31208 31219
26. BA Carlson MM Dubay EA Sausville L Brizuela PJ Worland 1996 Flavopiridol Induces G1 Arrest with Inhibition of Cyclin-dependent Kinase (CDK) 2 and CDK4 in Human Breast Carcinoma Cells Cancer Res 56 2973 2978
27. M Losiewicz B Carlson G Kaur E Sausville P Worland 1994 Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275 Biochem Biophys Res Commun 201 589 595
28. S McClue D Blake R Clarke 2002 In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) Int J Cancer 102 463 468
29. Squires MS, Feltell RE, Lock V et al (2007) AT7519, a potent CDK inhibitor, is active in leukemia models and primary CLL patient samples. ASH Annual Meeting Abstracts 110:3127
30. R Chen MJ Keating V Gandhi W Plunkett 2005 Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death Blood 106 2513 2519
31. R Merino L Ding D Veis S Korsmeyer G Nunez 1994 Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes EMBO J 13 683 691
32. JC Byrd TS Lin JT Dalton 2007 Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia Blood 109 399 404
33. KC Bible JL Lensing SA Nelson 2005 Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points Clin Cancer Res 11 5935 5941
34. R Chen WG Wierda S Benaissa 2007 Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol ASH Annual Meeting Abstracts 110 3112
35. E Heath K Bible R Martell D Adelman P Lorusso 2008 A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors Invest New Drugs 26 59 65
36. Hawtin RE, Cohen R, Haas N et al (2007) In: 12th congress of the European Hematology Association Vienna, Austria, June 7-10, 2007. Haematologica, p 276
37. Goldberg Z, Wierda W, Chen R et al (2008) In: 13th congress of the European Hematology Association Copenhagen, Denmark, June 12-15, 2008. Haematologica, p 327
38. P Bergsagel 2007 Individualizing therapy using molecular markers in multiple myeloma Clin Lymphoma Myeloma 7 Suppl 4 S170 S174
39. F Zhan Y Huang S Colla 2006 The molecular classification of multiple myeloma Blood 108 2020 2028
40. M Ali H Choy A Habib D Saha 2007 SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor Neoplasia 9 370 381
41. PL Bergsagel WM Kuehl F Zhan 2005 Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma Blood 106 296 303
42. Trudel S, Sebag M, Li ZH et al (2008) SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates preclinical activity in human multiple myeloma. AACR Meeting Abstracts 2008, p 4972
43. N Chiorazzi KR Rai M Ferrarini 2005 Chronic lymphocytic leukemia N Engl J Med 352 804 815